India's cheap weight-loss drugs could reshape global obesity fight
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"Prices are expected to fall sharply."
— Sheetal Sapale , Other
"It is great that these will become cheaper so that more of the diabetic and obese Indian population can access them."
— Muffazal Lakdawala , Other
Key People
Locations
All Coverage
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Similar Stories
Related coverage based on topic and tags
New weight-loss pill approved for use in UK
Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.
August 10, 2026 at 03:25 PMNovo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com
August 13, 2026 at 10:02 AMLilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PMWeekly type 2 diabetes jab could replace daily injections
Hundreds of thousands of people with type 2 diabetes could get access to a new weekly insulin jab to replace daily injections.
August 20, 2026 at 12:39 AM